2. About Us…

4. LOCATIONDOSAGE FORMAPPROVALS GOA I TABLETS, CREAMS & OINTMENTS US-FDA EU-GMP TGA Australia MCC South Africa ANVISA – Brazil GOA II STERILE PRODUCTS Same as above GOA III TABLETS US-FDA EU-GMP TGA Australia WALUJ TABLETS Emerging Markets BADDI TABLETS, LIQUID ORALS & TOOTHPASTES EU–GMP and Emerging Markets PATALGANGA APIs US-FDA, TGA Australia KILOLAB APIs US-FDA, TGA Australia Regulatory Approvals

5. Branded Generics Active Pharmaceutical Ingredients (APIs) (Captive Consumption & Supply to end users) Regulated Markets - Generics - CRAMS Emerging Markets - Branded Generics AnaCipher (Analytical Services) Xtend Industrial Designers and Engineers Business Model

6. Top Therapy Contributors 2013-2014 Indian Formulation Business Market Size Rs. 76,640 Crs Source : AWACs

7. Marketing DivisionsDoctor’s Specialties Covered INDOCO Multi Specialty Division with focus on Consulting Physicians SPADE Multi Specialty Division with focus on Consulting Physicians WARRENDentists EXCELOphthalmologists SPERAGynecologists, General Practitioners ETERNAOrthopedicians INDOCO CND Cardiologists, Diabetologists, Consulting Physicians HOSPITAL / INSTITUTIONHospitals (Private & Government ) TOP BRANDS FEBREX PLUS CYCLOPAM SENSODENT K ATM OXIPOD SENSOFORM CLOBEN G CITAL SENSODENT KF KARVOL PLUS Indoco generates 50 Million Prescriptions Annually (Source : CMARC) Indian Formulation Business

8. Increasing income levels, rapid urbanization, demand for quality healthcare services and changing lifestyle Brand building and focus on chronic segment Penetration in Northern and Eastern Regions to achieve regional balance New Products introductions (Around 20 products including brand extensions every year) Focus on developing sustainable Rx support from core prescribers of Indoco brands Significant API contribution with expanded product basket and services Indian Business - Growth Drivers

9. Revenue of Rs. 200 Crs in 2013-14 Revenue contribution (Europe 51%, USA 22 %, SA & ANZ 13%) CRAMS, FDF, APIs MAs / Dossier Out-Licensing Regulated Markets (87% of Exports) Revenue of Rs. 31 Crs in 2013-14 Revenue Contribution (Africa 8%, Asia 2%, Latam 2% ) Promotion of Branded Generics through Distributors Emerging Markets (13% of Exports ) International Business

10. Partnership and alliances to provide impetus to international business Regulatory approvals from countries including US / Europe for manufacturing facilities and products Own filing of ANDAs and Dossiers Shift from CRAMS to supplies against own dossiers / marketing authorizations in regulated markets Creation of own Intellectual Property through Patents and Trademarks NDDS and new platform technologies for future commercial exploitation International Business - Growth Drivers

11. Segment wise Break-up and Contribution

12. Highlights – Third Quarter & Nine Months Results FY15 (Rs. In Crs) Particulars Third QuarterNine Months TYPYGwth%TYPYGwth% Net Revenue21318813.063753219.9 EBITDA 433043.01288746.7 % to Sales20.115.8 20.116.4 PBT281856.0875074.8 % to Sales13.29.6 13.69.3 PAT221453.1643962.8 % to Sales10.17.5 10.17.4 Diluted EPS (Rs)2.351.536.954.27

13. 604 Dec'12 1263 Dec'13 2710 Dec'14 Increase in Shareholder’s Wealth Share Holding Pattern and MCAP (Rs. Crs)

14. Strategies – - Run healthy core businesses - Leverage strengths into new products and services - Open new frontiers, viz., CRO, Allied Services Core Competencies – - Detailed customer knowledge and focus - Large scale systems integration - Lean enterprise - To embark upon proactive measures (e.g. GST, SAP, IFRS,etc) Values – - Integrity - Quality - Customer satisfaction - Team spirit - Good corporate citizenship - Leadership Roadmap for Growth

15. Thank You Many Minds, Many Hands, One Goal